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Abstract
Enzyme inhibitory agents are attractive because of their application in treating different 
ailments. The absence of enzymes produce a number of diseases. Medicinal plants are a 
rich source of producing secondary metabolites which showed broad-spectrum enzyme 
inhibitory potential. The position of enzyme inhibitors as new drugs is vast since these 
compounds have been used for the treatment of various physiological disorders. Bioactive 
secondary metabolites can deliver excellent pharmacophore patterns for drugs related to 
numerous illnesses. This book chapter is planned to document the enzyme inhibitory 
potential of natural compounds, medicinal plant extract, and its isolated compounds.
Keywords: natural products, enzyme inhibitors, medicinal plants
1. Introduction
Medicinal plants are a rich source of producing bioactive natural products in most precise and 
selective way. Since the mid-nineteenth century, many natural products have been purified 
from plants, and most of them exist to be used as active elements of the modern medication. 
The search of excellence, real, inexpensive, and simply accessible natural compound enzyme 
inhibitor is one of the drug finding and strategy investigation works in the study organizations 
through the world [1].
Medicinal plants, extracts, and its fractions are used by 80% of the world population for 
their simple health necessities. The association among human, medicinal plants, and 
derived drugs from medicinal plants defines the past of men. Medicinal plants are the 
significant basis of natural drug molecules. The medicinal plants are expected to comprise 
secondary metabolites which have properties to use in modern medication for the cure of 
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various diseases which are not treatable. Throughout the historical period, old-style sys-
tems of medicine have developed a topic of global significance. Present approximations 
recommended that in numerous emerging republics a huge population trusts seriously on 
traditional specialist and medicinal plants to chance the main health care wants, though 
modern drug may be obtainable in these countries. Herbal medicines must frequently 
preserved approval for important and national reasons. Presently, several people in the 
advanced countries have initiated to go to another or complementary treatments, contain-
ing therapeutic herbs [2]. Ayurvedic medication for drug adjustment switches to medicinal 
plants. Ayurvedic medicine is a combination of numerous elements which is ready from 
medicinal plants, but the active compounds when purified from that medicinal natural 
plant source fail to provide the wanted activity. In the nonappearance of pharmacological 
data on several medicinal plants and isolated compounds which is not likely to regulate the 
vigorous compounds consuming wanted biological potency. Earlier trainings presented 
the poisonous properties of chemotherapy and radiation in handling of cancer by decrees 
by Ayurvedic medication, and wound curing might be complete by using Ayurvedic medi-
cine. Modern discipline production is an important part in this procedure, to grow natively 
establishing materials for wanted quality [3].
Enzyme inhibitors are mainly bioactive secondary metabolites that bind with an enzyme and 
decrease its bioactivity. Subsequently, blocking enzyme activity can kill a pathogen or correct a 
metabolic imbalance; many drug molecules are enzyme inhibitors, and mainly enzyme activa-
tors connect to various enzymes, increase their enzymatic actions, and subtract link and subse-
quently distort to products in the catalytic cycle of the enzymes. The linking of inhibitors can 
finish a substrate from the enzyme-active site and stays the enzyme in catalyzing in chemical 
reaction. Enzyme inhibition is both an irreversible and reversible process. The irreversible inhibi-
tors react with enzyme and adjust it chemically by a covalent likening formation. Then, these 
inhibitors adjust important amino acid remnants wanted from an enzymatic reversible inhibi-
tors which are non-covalently bonded; different types of inhibition are shaped depending on 
whether inhibitors link non-covalently, and dissimilar types of inhibition are shaped depending 
on whether these inhibitors bind to the enzyme and produced enzyme substrate complex or 
both [4].
Many natural products are enzyme inhibitors; the finding and development are dynamic 
areas of pharmacology and biochemistry. Medicinal enzyme inhibitors are frequently 
mediated by its specificity and its effectiveness that designated the absorption desirable 
to inhibit the enzyme. Great specificity and potency confirm that a medicinal drug will 
have few side effects and possess low toxicity. Natural enzyme inhibitors are involved 
in the guideline of much metabolic procedure. Actually, enzyme is a metabolic pathway 
which can be inhibited by many downstream yields. These types of bad response slow the 
manufacture line when product activates to shape up and a significant way to reserva-
tion homeostasis in cell. An additional cellular enzyme inhibitor is protein which specially 
binds and inhibits an enzyme objective. These help regulator enzymes which may be harm-
ful to cell alike proteases. The well-categorized example of this is the ribonuclease inhibitor 
that link ribonucleases in the tightest recognized protein contact. Many natural enzyme 
inhibitors may also be poisonous and are used as defenses besides predators as habits of 
killing several preys [4].
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2. Discovery and design of new enzyme inhibitors
Discovery of new drugs is actually the product of a very long drug growth procedure; the 
first step among which is the discovery of new enzyme inhibitors. In the past time, the only 
way to discover new drugs was a trial-and-error method, which proceeds to screen enormous 
libraries of chemical constituents against a marked enzyme and expect that maybe some valu-
able lead drugs will arise. This physical force method is still fruitful and has been lengthy by 
combinatorial chemistry methods that rapidly yield huge statistics of new, known, and novel 
molecules and high-throughput screening expertise to quickly screen these enormous chemi-
cal libraries for valuable new inhibitors [5].
Recently, it is reported that an alternative approach has been documented: rational new 
drug uses the three-dimensional chemical structure of an enzyme-active position to expect 
which compound potency to be the new inhibitors [6]. These predictions are then screening, 
and some of these screenings of compounds may be proven as novel inhibitors. These new 
inhibitors are then used to attempt to get a chemical structure of enzyme in an inhibitor/
enzyme complex to show how the chemical constituents are connecting to the active posi-
tion, presenting alteration to be complete to the inhibitor to try to optimize binding. This 
test and recovered cycle are then repeated until a suitably strong inhibitor is formed [7]. The 
computer-based methods of expecting the attraction of an inhibitor for an enzyme are also 
existence advanced; these are molecular docking [8] and molecular mechanics.
3. Main uses of enzyme inhibitors
The enzyme inhibitors are abundantly original in nature and considered as well as produced 
as a main part of pharmacology and biochemistry. Natural poisons are frequently enzyme 
inhibitors which have grown to defend a plant or animal against predators. These natural 
toxins comprised certain known poisonous compounds. Artificial inhibitors are mostly used 
as new drugs but also be used as insecticides such as malathion, herbicides, or glyphosate 
and may be used as disinfectants like triclosan. Some other artificial enzyme inhibitors block 
acetylcholinesterase, an enzyme which disrupts dejected acetylcholine, and are used as nerve 
agents in chemical warfare [9]. Pistagremic acid and di-naphthodiospyrol are isolated com-
pounds having enzyme inhibitory activity (Figure 1). Coenzyme folic acid is also linked to the 
anticancer drug methotrexate (Figure 2).
Figure 1. The chemical structure of natural enzyme inhibitor.
Natural Products as a Potential Enzyme Inhibitors from Medicinal Plants
http://dx.doi.org/10.5772/67376
167
4. Results and discussion
Compounds isolated from medical plants and its extract and frication have potential enzyme 
inhibitor. Natural products derived from plants have excellent enzymatic action.
4.1. Natural products as urease inhibitors
For global nitrogen cycle, which can occur in medicinal plants, fungi and various bacteria 
urease (EC 3.5.1.5) are leading enzymes. Such type of hydrolase speeds up to 100 folds of the 
rate of urea hydrolysis and converts to ammonia and carbon dioxide [10–13]. Meanwhile, this 
finding in medicinal plants including Canavalia ensiformis which belongs to Fabaceae, the ure-
ase has been fully explored and converted the innovative in the field of biochemistry learning 
as the principal enzyme to be crystallized [14, 15] and likewise confirmed to be firmly needy 
on nickel ions [6]. The requirement on Ni2+ ions for catalytic action is a sole piece of urease 
between hydrolytic enzymes [10, 12].
In 1995, Jabri and coworkers succeeded to fully report the three-dimensional structure of 
urease enzyme from crystallography studies done with urease enzyme derived from Klebsiella 
aerogenes [16]. Later on, additional structures were revealed for ureases identified in Bacillus 
pasteurii, Helicobacter pylori, and maximum newly C. ensiformis [17–19]. Certainly, the char-
acterization of the urease enzyme structure from a legume was central to improve and com-
prehend the supplies for ureolytic properties of this type of enzymes in diverse animals [20].
The countless resemblance of amino acid order among ureases since multiple origins recom-
mends a mutual family for this enzyme [21]. Urease enzyme part an elementary trimeric col-
lection with one, two, or three subunits that can combine creating dodecameric or hexameric. 
Each active position comprises two Ni2+ ions separately after all additional between 3.5 and 
3.7 Å, linked by oxygen particles of a lysine carbamate rest and a hydroxide ion [22].
Medicinal plants and fungus ureases showed a solitary polypeptide chain though bacteria which 
must be 2/3 of dissimilar subunits (A, B, and C) [23]. The combination of Ni2+ ions in protein 
structure is supported by additional proteins, supposed to be specific urease chaperones [23].
Figure 2. (A) Chemical structure of coenzyme folic acid (left side) associated to the anticancer drug methotrexate (right 
side). (B) The chemical structure of a complex between penicillin G and Streptomyces transpeptidase (produced from DB).
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Urease enzyme in the background of H. pylori, which raise the medium pH by the accretion of 
NH
3
, is a urease trait of great medical position [13]. Gastrointestinal infections or urine by ureo-
lytic bacteria can be a basis of health problems in humans and many other animals including 
pyelonephritis, kidney stone formation, ultimately hepatic coma, and hepatic encephalopathy 
[24]. Consequently, the main public health subjects are connected by H. pylori, Gram-negative 
bacteria that are bright to live in an environment as acidic as that of the stomach (pH 2–4). 
By way of significance, H. pylori poison can bring gastric irritation and raise the risk for the 
growth of duodenal, gastric adenocarcinoma, gastric ulcers, and gastric lymphoma [24].
Fifty percent of the universal population is dedicated by H. pylori. H. pylori can persevere in 
the stomach for the entire life of diseased persons without producing illness signs. The high 
occurrence of H. pylori in human population designates that such microorganism has estab-
lished mechanisms for confrontation against host fortifications [25]. The urease enzyme pres-
ent in cytoplasm or bound to H. pylori superficial is the chief virulence factor of such human 
pathogen [25]. It is suggested that the lyses of some pathogen cells tip to the issue of cytosolic 
ureases which connect to the superficial of intact bacterial cells and basis the hydrolysis of urea 
existing in human guts at an absorption of 3 mM. The NH
3
 fashioned raises the medium pH, 
which produces an outgoing location for H. pylori survival [26]. Throughout the past 20 years, 
the endorsed first-line therapy for H. pylori abolition contained the mixture of the antibiotics 
amoxicillin and clarithromycin with omeprazole, a proton pump cell inhibitor. The upsurge 
of H. pylori resistance to these antibiotics (chiefly to clarithromycin) completes this therapy 
which is a non-attractive choice in new ages [27]. Additional action plans have arose to compe-
tition H. pylori infections, which comprise the usage of bismuth salts joint with a proton pump 
cell inhibitor [28]. Furthermore, urease inhibitors might be active therapies for the cure of dis-
eases produced by urease-dependent pathogenic microorganisms. However, the commercially 
accessible urease inhibitors, including hydroxamic acid derivatives, phosphorodiamidates, and 
imidazoles, are toxic and have low stability, feature that stop their clinical usage [29]. The main 
search for new, known, novel, and bioactive urease inhibitors which enhanced stability and 
low toxicity is necessary to improve life excellence of human beings and animals.
4.2. Xanthine oxidase
Gout is a public illness with a universal spreading. Hyperuricemia, related with gout, is current 
in 5–30% of the overall people [30]. It appears to be growing universally and is measured as 
an important risk issue in thoughtful complaints similar to tophaceous gout, gouty nephropa-
thy, and nephrolithiasis [31, 32]. Hyperuricemia consequences from the overproduction or 
under-excretion of uric acid and is importantly unfair by the high dietary consumption of 
foods ironic in nucleic acids, such as meats, leguminous seeds, and certain kinds of sea food. 
Throughout the previous step of purine metabolism, xanthine oxidase catalyzes the oxidation 
of xanthine and hypoxanthine into uric acid uricosuric drugs which development the urinary 
removal of uric acid, and xanthine oxidase inhibitors which block the mortal step in uric acid 
bio-synthesis, can minor the plasma uric acid concentration, and are usually working for the 
conduct of gout [33]. Furthermore, xanthine oxidase helps as a significant organic source of 
oxygen resulting to free radicals that pay to oxidative damage of existing materials producing 
several extreme positions like inflammation, carcinogenesis, hepatitis, ischemia reperfusion, 
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as well as elderly [34, 35]. Allopurinol is the individual clinically used xanthine oxidase inhibi-
tor in the cure of gout [36]. This drug bases countless side effects including nephropathy, 
hepatitis, and allergic responses [37]. Thus, the exploration for new xanthine oxidase inhibi-
tors with advanced therapeutic potential and less side effects wanted not only to treat gout but 
also fight numerous additional diseases connected with xanthine oxidase action.
4.3. Angiotensin-converting enzyme
Angiotensin I-converting enzyme action (ACE, peptidyldipeptide hydrolase, kininase II, EC 
3.4.15.1) plays a significant part in ruling of blood pressure [38]. Angiotensin I-converting 
enzyme is a significant blood pressure controller that catalyzes the release of His-Leu from 
the carboxyl irredeemable angiotensin I, which, in go, produces a strong vasopressor octa-
peptide, angiotensin II. Angiotensin I-converting enzyme is also complicated in the poverty 
of vasodilator bradykinin [39]. The greatest if not all commercialized angiotensin I-converting 
enzyme inhibitors have developed peptides from the venom of the Brazilian viper Bothrops 
jararaca as classical materials [40]. Also, this animal basis, microorganisms, and plants deliver 
chemical substances with angiotensin I-converting enzyme inhibitory activity which might 
help as perfect materials in the growth of new angiotensin I-converting enzyme inhibitors. 
Angiotensin I-converting enzyme inhibitors prevent the formation of angiotensin II by ACE 
and thus decrease outlying vascular confrontation and blood pressure. These synthetic drugs 
are supposed to have sure side effects such as cough, taste conflicts, and skin rashes [41]. 
Consequently, for safe and cost-effective use, curiosity in finding food sources as angiotensin 
I-converting enzyme inhibitor has improved. Further compelling angiotensin I-converting 
enzyme inhibitors have been intended and synthesized to indulgence of hypertension excel-
lently. Oral management of these drugs regularly results in unsolicited side effects; nutri-
tional method strength be a healthier medium by which blood pressure in skillful. Besides, 
some trainings obligate been made on single plant species where several classes of angioten-
sin I-converting enzyme inhibitory molecules must be recognized, such as flavonoids, xan-
thones, proanthocyanidins, secoiridoids, and peptides for a complete evaluation of natural 
compounds [42–48].
4.4. α-Amylase
α-Amylase is a protein enzyme (EC 3.2.1.1) which hydrolyses α bonds of big, α-bonded poly-
saccharides, including starch and glycogen, elastic glucose, and maltose [49]. That is the main 
form of the amylase existing in humans and other mammals [50, 51]. It is also existing in seeds 
covering starch as a food reserve, which is secreted by many fungi.
Though it originates in numerous tissues, amylase is greatest projecting in saliva and pancre-
atic juice, and all of them have its individual isoform of human α-amylase. They act inversely 
on isoelectric focusing, and also be detached in testing by consuming precise monoclonal 
antibodies. Amylase is created in saliva and disruption starch into maltose and dextrin. This 
form of amylase is also called ptyalin. It will break down bulky, insoluble starch molecules 
into soluble starches making consecutively minor starches and finally maltose. Ptyalin per-
formances on linear α(1–4) glycosidic linkages, but parts hydrolysis wants an enzyme that 
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presentations on cleft products. Gastric acid deactivates the salivary amylase in the stomach. 
In gastric juice agreed to pH near to 3.3–4, where ptyalin was deactivated completely at 37°C 
in 20 min. In difference, 50% of amylase activity is sustained after 150 min of introduction to 
gastric juice at pH 4.3 [52, 53]. Together, starch and substrate for ptyalin and then product 
(glucose of short chains) are capable to partly defend it touching in-activation by gastric acid. 
Ptyalin additional to buffer at pH 3.0 underwent whole inactivation in 120 min; adding of the 
starch at a 0.1% level caused 10% of the activity residual, and similar addition of starch to a 
1.0% level produced about 40% of the activity residual at 120 min [54].
4.5. α-Glucosidase enzymes
Alpha-glucosidase; α-glucopyranoside; glucoinvertase; including glucoamylase, malt-
ase, glucosidosucrase, maltase, glucosidoinvertase, alpha-d-glucosidase, hydrolase, α-1,4-
glucosidase, and α-d-glucoside glucohydrolase are glucosidases positioned in the brush end 
of the small intestine which acts upon α(1–4) bonds [55–61]. In dissimilarity to β-glucosidase, 
the α-glucosidase decomposes starch and disaccharides in to glucose. In the meanwhile malt-
ase enzyme decompose maltose is nearly functionally equal.
The key role of α-glucosidase is to hydrolyze incurable nonreducing (1–4) attached α-glucose 
which remains to release a lonely α-glucose molecule [62]. α-Glucosidase is mainly a carbohydrate 
which hydrolyzes the releases of α-glucose which is different to β-glucose. β-Glucose remains 
unconfined through glucoamylase, a similar enzyme. The substrate molecule discrimination of 
α-glucosidase is outstanding to subsite attractions of the active site of enzymes [62]. The main 
proposed mechanism comprises a nucleophilic shift of intermediate (oxocarbenium ion) [62].
Blood-sucking insect (Rhodnius prolixus) produces hemozoin when it digests hemoglobin 
of the host. The synthesis of hemozoin is reliant on the substrate connected to the site of 
α-glucosidase [63].
It has been documented in literature that α-glucosidases were extracted and then character-
ized from trout liver which exhibited maximum activity of the enzyme with increase rate that 
is 80% throughout workout in contrast to a latent trout.
This alteration was shown in correlation to the effects rise for liver glycogen phosphorylase.
From this it was offered that α-glucosidases in the glucosidic track play a significant portion in 
adding the phosphorolytic path in the livers’ metabolic action to energy pressures of exercise.
The slight intestine of rat and yeast has α-glucosidases which exhibited to be reserved by 
numerous groups of flavonoid moiety [63].
Our research group has also reported phosphodiesterase-1 inhibitory, urease inhibition, and 
β-secretase enzyme effect of many natural products [64–67]. Novel glycine and phenylalanine 
sulfonamide derivatives have been reported for carbonic anhydrase inhibition activity [68]. 
It has recently documented that bovine liver tissue on glutathione reductase (GR) enzyme 
resolves the effects of adrenaline, thiamine, tyrosine, and dopamine. The bovine liver GR 
also effects on some natural amine [69]. Furthermore, the effects of particular catecholamines 
of the properties of carbonic anhydrase enzyme purified from bovine kidney tissue are also 
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documented. Some synthetic sulfonamides which contain molecules have also documented 
in literature for urease inhibition potential [70].
5. Conclusion
In conclusion medicinal plants and derived natural products from plants have potential 
enzyme inhibitor. This book chapter directed researcher to isolate bioactive compounds from 
plants which have excellent enzymatic action. Thus, the exploration for new, known, and 
novel enzyme inhibitors with progressive therapeutic potential and fewer side effects are 
required to treat diseases in mankind as well as in animals.
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